Want to see HK:0574 full AI Analyst Report?
0574 Stock Chart & Stats
HK$0.05
<HK$0.01(2.04%)
At close: 4:00 PM EST
HK$0.05
<HK$0.01(2.04%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.06
Previous CloseN/A
Volume290.00K
Average Volume (3M)1.15M
Market Cap
HK$39.82M
Enterprise ValueHK$281.96
Total Cash (Recent Filing)HK$5.53M
Total Debt (Recent Filing)HK$205.79M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,212,489,300
10 Day Avg. Volume798,200
30 Day Avg. Volume1,152,533
Financial Highlights & Ratios
PEG Ratio-1.16
Price to Book (P/B)-0.36
Price to Sales (P/S)0.61
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Restored Operating Profitability (2025)The company posted positive operating profit and EBITDA in 2025, indicating it can generate operating-level profits through cost control or improved sales mix. If sustained, this supports internal cash generation potential, reduces reliance on external financing, and provides a foundation for durable margin recovery.
Lower Reported Debt Vs 2023Material reduction in debt versus 2023 lowers immediate refinancing and interest burdens, improving solvency headroom. Reduced leverage gives management more flexibility to fund operations or restructure without immediate asset sales or severe dilution, enhancing multi‑month financial resilience.
Evidence Of Revenue Rebound (2023)The 2023 rebound with revenue growth and positive net income demonstrates the business can regain top-line momentum and translate it to profits under the right conditions. This historical recovery indicates underlying market demand and product viability that can be targeted for a sustained multi‑month turnaround.
Bears Say
Persistently Negative Shareholders' EquityNegative shareholders' equity over multiple years is a fundamental solvency red flag that limits borrowing capacity and creditor confidence. It increases the likelihood management must pursue dilutive capital raises or asset sales, constraining strategic options and long‑term financial stability.
Consistent Negative Cash GenerationThe company generates negative operating and free cash flow in every reported year, indicating structural cash burn. Persistent cash deficits force reliance on external financing, weaken investment capacity for growth or R&D, and leave the business exposed to funding market cycles over the medium term.
Revenue Volatility And Renewed ContractionTop-line volatility and renewed contraction in 2024–2025, coupled with recurring net losses, signal unstable demand and fragile earnings quality. Continued revenue decline erodes scale economics and makes margin recovery more difficult, pressuring profitability and operational sustainability unless growth stabilizes.
Pa Shun International Holdings Limited News
0574 FAQ
What was Pa Shun International Holdings Limited’s price range in the past 12 months?
Pa Shun International Holdings Limited lowest stock price was HK$0.02 and its highest was HK$0.06 in the past 12 months.
What is Pa Shun International Holdings Limited’s market cap?
Pa Shun International Holdings Limited’s market cap is HK$39.82M.
When is Pa Shun International Holdings Limited’s upcoming earnings report date?
Pa Shun International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 22 days.
How were Pa Shun International Holdings Limited’s earnings last quarter?
Pa Shun International Holdings Limited released its earnings results on Mar 30, 2026. The company reported -HK$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pa Shun International Holdings Limited overvalued?
According to Wall Street analysts Pa Shun International Holdings Limited’s price is currently Overvalued.
Does Pa Shun International Holdings Limited pay dividends?
Pa Shun International Holdings Limited pays a Monthly dividend of HK$0.023 which represents an annual dividend yield of N/A. See more information on Pa Shun International Holdings Limited dividends here
What is Pa Shun International Holdings Limited’s EPS estimate?
Pa Shun International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pa Shun International Holdings Limited have?
Pa Shun International Holdings Limited has 2,212,489,300 shares outstanding.
What happened to Pa Shun International Holdings Limited’s price movement after its last earnings report?
Pa Shun International Holdings Limited reported an EPS of -HK$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.793%.
Which hedge fund is a major shareholder of Pa Shun International Holdings Limited?
Currently, no hedge funds are holding shares in HK:0574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pa Shun International Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
Pa Shun International Holdings Limited
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Pa Shun International Holdings Limited operates as a subsidiary of Praise Treasure Limited.
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Pak Fah Yeow International Limited
―